Cybin Inc (NEO:CYBN) — Market Cap & Net Worth
Market Cap & Net Worth: Cybin Inc (CYBN)
Cybin Inc (NEO:CYBN) has a market capitalization of $301.37 Million (CA$416.62 Million) as of June 18, 2026. Listed on the NEO stock exchange, this Canada-based company holds position #14911 globally and #444 in its home market, demonstrating a -22.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cybin Inc's stock price CA$8.35 by its total outstanding shares 49894131 (49.89 Million). Review total liabilities of Cybin Inc to assess the company's total debt and financial obligations.
Cybin Inc Market Cap History: 2020 to 2026
Cybin Inc's market capitalization history from 2020 to 2026. Data shows change from $2.59 Billion to $301.37 Million (-24.13% CAGR).
Cybin Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cybin Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2381.11x
Cybin Inc's market cap is 2381.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.06 Billion | $864.00K | -$32.22 Million | 2381.11x | N/A |
Competitor Companies of CYBN by Market Capitalization
Companies near Cybin Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Cybin Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Cybin Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Cybin Inc's market cap moved from $2.59 Billion to $ 301.37 Million, with a yearly change of -24.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$301.37 Million | -24.84% |
| 2025 | CA$400.99 Million | -12.52% |
| 2024 | CA$458.38 Million | -36.94% |
| 2023 | CA$726.91 Million | +27.71% |
| 2022 | CA$569.18 Million | -72.33% |
| 2021 | CA$2.06 Billion | -20.63% |
| 2020 | CA$2.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Cybin Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $301.37 Million USD |
| MoneyControl | $301.37 Million USD |
| MarketWatch | $301.37 Million USD |
| marketcap.company | $301.37 Million USD |
| Reuters | $301.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more